DreaMed Diabetes is a medical device and SaaS company that specializes in personalized diabetes treatment optimization solutions. Founded in 2014, the company initially gained recognition for commercializing the first artificial pancreas technology, featured in the NEJM. DreaMed Diabetes has since concentrated on developing decision support tools in diabetes management and stands out as the only company globally to secure FDA clearance for a decision support system utilizing data from CGM/SMBG and insulin pumps.
The company's Advisor Pro software, developed by diabetes experts and enhanced by artificial intelligence, is a clinically proven decision support system aimed at insulin titration for type 1 diabetes patients. This innovative system enables healthcare professionals to efficiently analyze patient data and recommend optimal treatment plans, ultimately empowering physicians and nurses to provide personalized, high-standard care regardless of location or caregiver. With frequent titration adjustments and online monitoring, DreaMed Diabetes helps patients achieve better treatment outcomes, lowering their A1C levels and reducing the risk of complications.
Attracted a $5.00M grant investment on 16 September 2020 from The Leona M. and Harry B. Helmsley Charitable Trust, DreaMed Diabetes continues to make strides in empowering healthcare professionals with AI-driven diabetes care and improving patient outcomes worldwide.
